Baxdela Tablet
Product Images NDC 70842-101

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Baxdela (NDC 70842-101). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Melinta Therapeutics, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Baxdela 01)

Chemical structure diagram showing the molecular composition of delafloxacin meglumine, the active ingredient in Baxdela. The structure includes fluorine, chlorine, nitrogen, oxygen, and carbon atoms arranged in a complex bicyclic system with attached functional groups.*

FDA Label Image

Principal Display Panel (450 mg Tablet Bottle Carton)

Baxdela 450 mg per tablet blister carton for delafloxacin tablets. The packaging indicates 20 tablets (2 blister cards of 10 tablets each) and shows the labeler Melinta Therapeutics, LLC. The design includes the brand name, strength, and usage instructions for pharmacists to dispense with medication guide.*

FDA Label Image

Principal Display Panel (300 mg Vial Carton)

Flat packaging label for Baxdela (delafloxacin) tablets 450 mg per tablet by Melinta Therapeutics. The label states the product contains 20 tablets, is prescription-only, and includes storage instructions, excipients, and a dispensing reminder to pharmacists. The label features teal and white colors with the Melinta Therapeutics logo and barcodes.*

FDA Label Image

Baxdela 04

Baxdela 300 mg/vial injection lyophilized powder for solution is shown on the label. It is an intravenous single-dose vial containing delafloxacin. The label includes dilution instructions, excipients, storage conditions, and the Melinta Therapeutics, LLC distributor information with barcode and QR code present.*

FDA Label Image

Baxdela 05

The image shows the packaging label design for Baxdela (delafloxacin) injection, 300 mg per single-dose vial. It is a lyophilized powder for intravenous infusion, with instructions for reconstitution and dilution. The label includes branding, dosage form, strength, manufacturer Melinta Therapeutics, LLC, storage conditions, and a 10-vial count indication.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.